HeartBeam sees HeartBeam AIMI to be cleared in Q1 time frame

HeartBeam issued a letter to shareholders from its Chief Executive Officer and Founder, Branislav Vajdic, PhD. That letter said in part: "2022 was a transformative year for HeartBeam and for our technology and business, highlighted by ongoing advancements in our product launch timeline for the HeartBeam AIMIGo 12-Lead 3D Vector Electrocardiogram ECG Device and HeartBeam AIMI…Developed by our pioneering team, our HeartBeam AIMI and HeartBeam AIMIGo solutions will transform the way patients and doctors detect heart attacks. By providing remote, 12-lead 3D vector ECG VECG capability, the HeartBeam platform intends to offer fast, accurate detection of heart attacks and complex cardiac arrhythmias for the first time outside of a medical setting. We expect the HeartBeam AIMI system for use in acute care settings to receive regulatory approval in the near future. We are in discussions with the FDA and plan to meet with them soon and expect HeartBeam AIMI to be cleared in the Q1 2023 time frame ..We plan to focus in 2023 and 2024 on the expansion of our core technology features, the 3D VECG data and clinical studies that we believe will establish our platform as the standard of care for ambulatory-based cardiology and taking advantage of the comprehensiveness of our technology."